Some 12% — or about 1 in 8 — people living in the U.S. have tried a GLP-1 drug, according…
Read More »GLP1
A new study by researchers at Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system,…
Read More »MIAMI, FL, Oct. 16, 2024 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: NASDAQ:), a late clinical stage biopharmaceutical company focused on…
Read More »GLP-1s, or glucagon-like peptide-1 agonist drugs, are seemingly everywhere. In recent years, this class of weight-loss and Type 2 diabetes…
Read More »It seems like every day there’s a new supplement claiming to improve some facet of your health. Chances are, you’ve…
Read More »A Cleveland Clinic study identified key factors that can impact the long-term weight loss of patients with obesity who were…
Read More »Listen to the article 7 min This audio is auto-generated. Please let us know if you have feedback. The…
Read More »Sep. 10, 2024 6:56 PM ETNovo Nordisk A/S (NVO) Stock, LLY StockAMGN, JNJ, RHHBY, PFE, MRK, AZN, VKTX, GPCRBy: Val…
Read More »As recently as the onset of COVID-19 four years ago, you probably didn’t know what a glucagon-like peptide 1 agonist,…
Read More »Nestlé is launching its first major U.S. brand in nearly three decades as the food giant looks to meet the needs…
Read More »